reports
Repligen Corp: 1 director
A director at Repligen Corp sold 26,447 shares at 123.707USD and the significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...
Repligen Corporation to Present at Upcoming May Investor Conferences
Repligen Corporation to Present at Upcoming May Investor Conferences WALTHAM, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participating at the following May investor conferences. RBC Capital Markets’ 2025 Global Healthcare Conference, being held in New York on May 20-21. Jason K. Garland, Chief Financial Officer, is scheduled to participate in an analyst-led discussion on May 20 at 3:35 p.m. ET, in addition to a series of one-on-one meetings with investo...
Repligen Reports First Quarter 2025 Financial Results
Repligen Reports First Quarter 2025 Financial Results Revenue of $169 million, year-over-year increase of 10% as reported and 14% organic non-COVID growthOrders increased sequentially and high-teens year-over-year Adjusted operating income increased 72% year-over-year Reiterates 2025 full year organic revenue guidance of 9.5% - 13.5% WALTHAM, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its first quarter of 2025, covering the three-month period en...
Repligen to Report First Quarter 2025 Financial Results
Repligen to Report First Quarter 2025 Financial Results Webcast and Conference Call to Be Held Tuesday, April 29, 2025, at 8:30 a.m. ET WALTHAM, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first quarter 2025 financial results on Tuesday, April 29, 2025. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. ET to discuss business updates and financial results for the three- month reporting period ended March 31, 2025. The conference call will be accessi...
Repligen Appoints Jacob Johnson As Vice President Investor Relations
Repligen Appoints Jacob Johnson As Vice President Investor Relations WALTHAM, Mass., April 08, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment of Jacob Johnson as Vice President, Investor Relations. In this role, Mr. Johnson will lead the investor relations team’s engagement with the investment community, reporting to the company’s Chief Financial Officer, Jason K. Garland. Most recently, Mr. Johnson served as Managing Director, Research Analyst at Stephens Inc., where he followed the life sciences tools and pharma services sector. Mr. Garlan...
Repligen Purchases Bioprocessing Analytics Portfolio from 908 Devices
Repligen Purchases Bioprocessing Analytics Portfolio from 908 Devices Portfolio includes PAT devices for real-time process monitoring, control and analysis WALTHAM, Mass. and BOSTON, March 04, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RGEN), a life sciences company focused on bioprocessing technology leadership, and . (Nasdaq: MASS), a pioneer in purpose-built handheld and desktop devices for chemical analysis, announce that Repligen has purchased 908 Devices’ desktop portfolio of four devices for bioprocessing process analytical technology (PAT) applications. 908 Devices remains focused on th...
Repligen Reports Fourth Quarter and Full Year 2024 Financial Results
Repligen Reports Fourth Quarter and Full Year 2024 Financial Results Fourth quarter revenue of $168 million and full year revenue of $634 millionFourth quarter orders and revenues sequentially increased 11% and 8% respectivelyOrders outpaced revenue by 6% in the fourth quarter Provides full year 2025 guidance of 8% to 12% reported growth and 10% to 14% excluding COVID-related revenue WALTHAM, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its fourth...
Repligen to Report Fourth Quarter and Full Year 2024 Financial Results
Repligen to Report Fourth Quarter and Full Year 2024 Financial Results Webcast and Conference Call to Be Held Thursday, February 20, 2025, at 8:30 a.m. ET WALTHAM, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its fourth quarter 2024 financial results on Thursday, February 20, 2025. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. ET to discuss business updates and financial results for the three- and twelve- month reporting periods ended December 31, 202...
Repligen Corporation to Present at 43rd Annual J.P. Morgan Healthcare ...
Repligen Corporation to Present at 43rd Annual J.P. Morgan Healthcare Conference WALTHAM, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in the 43rd Annual J.P. Morgan Healthcare Conference, being held January 13 – 16 in San Francisco. Olivier Loeillot, President and Chief Executive Officer, will present an overview of the company on Tuesday, January 14 at 1:30 p.m. PT. A live webcast of the conference presentation will be accessible through Repli...
Repligen Launches the CTech™ SoloVPE® PLUS System
Repligen Launches the CTech™ SoloVPE® PLUS System Next-Generation At-Line Concentration Measurement for Bioprocessing WALTHAM, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the commercial launch of its CTech™ SoloVPE® PLUS System, the most advanced UV-based Variable Pathlength Technology system now available to biopharmaceutical manufacturers. The SoloVPE PLUS System is engineered to offer unparalleled accuracy, speed, and ease-of-use for at-line ultraviolet-visible (UV...
Repligen Announces Publication of the Company’s 2023 Corporate Sustain...
Repligen Announces Publication of the Company’s 2023 Corporate Sustainability Report WALTHAM, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of its 2023 Corporate Sustainability Report and related reporting framework disclosures. Themed “”, this newly reformatted report streamlines the company’s progress in advancing our sustainability strategy across six key impact areas: Products & Packaging, Operations, Talent, Supply Chain, Communities and Partn...
Repligen Launches Novel AVIPure® dsRNA Resin in OPUS® Pre-packed Colum...
Repligen Launches Novel AVIPure® dsRNA Resin in OPUS® Pre-packed Columns Breakthrough Innovation for the Purification of mRNA Therapeutics and Vaccines WALTHAM, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the launch of AVIPure® dsRNA Clear OPUS® columns, a groundbreaking solution designed to simplify and enhance the production of mRNA therapeutics and vaccines. This novel affinity chromatography offering marries Repligen’s breakthrough dsRNA purification resin with it...
- Jonathan Moreland
RMAX RE/MAX HOLDINGS INC.
RGEN REPLIGEN CORPORATION
PSEC PROSPECT CAPITAL CORPORATION
OPK OPKO HEALTH INC.
NMFC NEW MOUNTAIN FINANCE CORPORATION
IRWD IRONWOOD PHARMACEUTICALS INC. CLASS A
GLP GLOBAL PARTNERS LP
EL ESTEE LAUDER COMPANIES INC. CLASS A
AXSM AXSOME THERAPEUTICS
APPS DIGITAL TURBINE
ACRS ACLARIS THERAPEUTICS INC.
ENPH ENPHASE ENERGY INC.
HTLD HEARTLAND EXPRESS INC.
MBIN MERCHANTS BANCORP
FSLY FASTLY
NOVA SUNNOVA ENERGY INTERNATIONAL
GRWG GROWGENERATION
RWAY RUNWAY GROWTH FINANCE CORP
HYLN HYLIION HOLDINGS CORP.
SYRS SYROS PHARMACEUTICALS INC.
Repligen Reports Third Quarter 2024 Financial Results
Repligen Reports Third Quarter 2024 Financial Results Third quarter reported revenue of $155 million, an increase of 10% year-over-yearCDMO revenue and orders both up ~20% year-over-yearOverall order intake outpaced sales by 4% Full year revenue guidance narrowed to range of $630-$639 million WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its third quarter (Q3) of 2024, covering the three- and nine- month periods ended September 30, 2024. Pro...
Repligen Corporation to Present at Upcoming Investor Conferences
Repligen Corporation to Present at Upcoming Investor Conferences WALTHAM, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be presenting at three upcoming investor conferences. The UBS Global Healthcare Conference being held November 11-14 in Rancho Palos Verdes, CA. Jason Garland, Chief Financial Officer, will participate in an analyst-led discussion on Thursday, November 14, at 10:15 a.m. ET.The Stifel Healthcare Conference being held November 18-19 in New ...
Repligen to Report Third Quarter 2024 Financial Results
Repligen to Report Third Quarter 2024 Financial Results Webcast and Conference Call to Be Held Tuesday, November 12, 2024, at 8:30 a.m. ET WALTHAM, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its third quarter 2024 financial results on Tuesday, November 12, 2024. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. ET to discuss business updates and financial results for the three- and nine- month reporting periods ended September 30, 2024. Olivier Loeil...
Repligen Opens Training & Innovation Center to Elevate Customer Experi...
Repligen Opens Training & Innovation Center to Elevate Customer Experience WALTHAM, Mass., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the grand opening of its Repligen Training & Innovation Center (“RTIC”) at its Waltham headquarters. The opening celebration, held on the evening of September 23, attracted a group of over 150 biopharma and CDMO customers. The RTIC buildout, which features product exhibits, purpose-built demonstration areas and technical training space, was de...
Repligen Corporation to Present at Wells Fargo Healthcare Conference
Repligen Corporation to Present at Wells Fargo Healthcare Conference WALTHAM, Mass., Aug. 23, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be presenting at the Wells Fargo Healthcare Conference being held September 4-6 in Boston. Olivier Loeillot, President and Chief Executive Officer will participate in an analyst-led discussion on Friday, September 6, at 8:45 a.m. ET. A live webcast of the conference presentation will be accessible through Repligen’s website at , and wi...
Repligen Reports Second Quarter 2024 Financial Results
Repligen Reports Second Quarter 2024 Financial Results Reports second quarter revenue of $154 millionSecond quarter orders of $157 millionBook-to-bill 1.02 for the quarter, 1.01 year-to-dateAchieved first half revenue and order targetsNarrows revenue guidance within previous range for fiscal year 2024; adjusted EPS guidance unchanged WALTHAM, Mass., July 30, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its second quarter (Q2) of 2024, covering the three- and six- m...
Repligen Announces Agreement to Acquire Chromatography Innovator Tantt...
Repligen Announces Agreement to Acquire Chromatography Innovator Tantti Proposed acquisition adds novel macroporous chromatography base bead technology for downstream bioprocess applicationsAccelerates expansion into new modality markets with a unique, scalable purification solutionStrongly synergistic with AVIPure® affinity ligands and OPUS® pre-packed chromatography columns WALTHAM, Mass., July 29, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has entered into a definitive...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.